#United States #Cincinnati #Sirius Medical #Pintuition #Mammotome

Mammotome and Sirius Medical: A New Era in Breast Care

Mammotome, a renowned leader in breast care solutions, has officially announced a partnership with Sirius Medical, the pioneering force behind Surgical Marker Navigation. This collaboration aims to distribute the innovative Sirius Pintuition® System across the United States and Germany, marking a significant step forward in the domain of breast cancer treatment.

Breast cancer remains a pressing global health issue, necessitating advancements in medical technology to improve patient outcomes. The Sirius Pintuition® System offers surgeons greater accuracy in tumor excision by replacing traditional localization techniques with state-of-the-art Surgical Marker Navigation. This ground-breaking technology not only enhances surgical precision but also streamlines the entire procedure, ultimately benefiting patient recovery.

Bram Schermers, CEO of Sirius Medical, expressed enthusiasm about this partnership, stating, "We are thrilled to partner with Mammotome in our mission to advance breast cancer care. This collaboration will allow us to expand our footprint in critical markets and empower more surgeons with precise, efficient tools that transform patient outcomes."

Mammotome's vast experience in the breast care sector positions it uniquely to introduce the Pintuition® System effectively. The company possesses an extensive sales network throughout the U.S. and Germany, which will ensure healthcare facilities and surgeons have convenient access to this advanced technology, alongside Mammotome's comprehensive suite of premium breast care products.

Sarah Moore, Senior Vice President and Chief Commercial Officer of Mammotome, shared her excitement about this venture: "The Pintuition® System aligns with Mammotome's commitment to bring innovative, high-quality solutions to healthcare providers and their patients. We're excited to introduce this advanced technology to healthcare facilities and help enhance the quality of care for breast cancer patients."

This partnership underscores the shared dedication of both organizations to drive significant advancements in breast cancer treatment. By providing cutting-edge surgical tools, they aim to facilitate optimal patient care and outcomes. Moreover, the Pintuition® System will complement existing products like the Neoprobe® Gamma Detection System and HydroMARK™ Plus Breast Biopsy Site Marker, offering clinicians a robust portfolio of technologies to address all breast surgical needs effectively.

The Sirius Pintuition® System has already garnered positive attention, being both CE-marked and FDA-cleared, indicating its readiness for widespread clinical application. With over 35,000 procedures conducted globally across more than 225 centers, the system has proven its efficacy and reliability, paving the way for Mammotome to further enhance its product offerings in this vital field.

In addition to furthering technological advancements, this collaboration illustrates a strong commitment to improving the overall landscape of breast cancer treatment. By enhancing accessibility to innovative surgical tools, Mammotome and Sirius Medical aim to redefine the standards of care within surgical settings.

For more information about Mammotome and their innovative solutions in breast care, visit Mammotome.com.

About Mammotome

Mammotome is dedicated to excellence in breast care, merging expertise in medical technology with a compassionate approach towards patients and clinicians alike. Headquartered in Cincinnati, Ohio, the company aligns its mission with that of its parent organization, Danaher, a prominent leader in global science and technology, to drive significant advancements in human health.

About Sirius Medical

Sirius Medical, with ties to the Netherlands Cancer Institute, focuses on enhancing cancer care through innovative, efficient, and economical solutions for tumor removal. Their commitment to delivering superior surgical technologies continues to reshape the future of oncology practices worldwide.